Merck to acquire HUB Organoids to advance cell culture portfolio

Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development

Zaynich enables US cancer patient undergo successful liver transplant and resume chemotherapy

In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND

Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program

Granules India FDA approval for ADHD treatment

Merck announces FDA acceptance of biologics license application for Clesrovimab

An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care

Harnessing advanced data analysis for early detection, prevention and better outcomes

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines

Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio

The trademark rights for these brands will be transferred to Lupin by March next year.

Lonza outlines strategy, new organizational structure and guidance

The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities